Literature DB >> 7707816

Tumour suppressor genes in disease and therapy.

G R Skuse1, J W Ludlow.   

Abstract

Mesh：

Year:  1995        PMID： 7707816     DOI： 10.1016/s0140-6736(95)90015-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study.

Authors:  Carmela Di Gregorio; Piero Benatti; Lorena Losi; Luca Roncucci; Giuseppina Rossi; Giovanni Ponti; Massimiliano Marino; Monica Pedroni; Alessandra Scarselli; Barbara Roncari; Maurizio Ponz de Leon
Journal:  Int J Colorectal Dis       Date:  2004-12-09       Impact factor: 2.571

2.  The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q.

Authors:  A Borkhardt; S Bojesen; O A Haas; U Fuchs; D Bartelheimer; I F Loncarevic; R M Bohle; J Harbott; R Repp; U Jaeger; S Viehmann; T Henn; P Korth; D Scharr; F Lampert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.

Authors:  Debnath Mukhopadhyay; Shrikant Anant; Robert M Lee; Susan Kennedy; David Viskochil; Nicholas O Davidson
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

4.  Drug resistance in ovarian cancer - the role of p53.

Authors:  R Petty; A Evans; I Duncan; C Kurbacher; I Cree
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

5.  Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.

Authors:  R Saso; S Kulkarni; P Mitchell; J Treleaven; G J Swansbury; J Mehta; R Powles; S Ashley; A Kuan; T Powles
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.